CASI Pharmaceuticals, Inc.
CASIF OTC
SEC CIK 1962738
Follow CASI Pharmaceuticals
Weekly email: filings, results
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $20.7M | −$48.1M |
| FY24 | $28.5M | −$39.3M |
| FY23 | $33.9M | −$27M |
| FY22 | $38M | −$41M |
| FY21 | $30M | −$36.7M |
| FY20 | $15M | −$48.3M |
| FY19 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 48.6% | −217.3% | −232% |
| FY24 | 39.1% | −138.8% | −137.6% |
| FY23 | 59.2% | −74% | −79.6% |
| FY22 | 71.7% | −89.4% | −107.8% |
| FY21 | 58.7% | −138.3% | −122.1% |
| FY20 | 37.6% | −351.8% | −321.9% |
| FY19 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$20.8M |
| FY24 | −$29.4M |
| FY23 | −$20.2M |
| FY22 | −$26.7M |
| FY21 | −$35.8M |
| FY20 | −$27.4M |
| FY19 | - |
- CASI Pharmaceuticals
- Healthcare median
Show the numbers
| Year | CASI Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −232% | −30.6% |
| FY24 | −137.6% | −47% |
| FY23 | −79.6% | −58% |
| FY22 | −107.8% | −80.4% |
| FY21 | −122.1% | −71.9% |
| FY20 | −321.9% | −62.2% |
| FY19 | - | −46.3% |